Hospital
Last Frontier Healthcare District
Last Frontier Healthcare District was paid $8.55M by Medicaid between Jan 2018 and Nov 2024, across 95 billing codes. Its largest line is 99283, emergency room visit (moderate) — 30% of everything it billed.
33Billing provider infoLAST FRONTIER HEALTHCARE DISTRICT
ALTURAS, CA 96101
ALTURAS, CA 96101
33aNPI1487669032assigned 07/30/2006
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$8.55M
24GClaims120,474
24DCodes billed95
24AFirst – last monthJan 2018 – Nov 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,912 | $695K | |
| 2019 | 15,388 | $931K | |
| 2020 | 14,826 | $1.12M | |
| 2021 | 20,561 | $1.57M | |
| 2022 | 22,125 | $1.74M | |
| 2023 | 19,437 | $1.39M | |
| 2024incomplete | 13,225 | $1.11M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 30% | 20,469 | 13,837 | $2.58M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 18% | 9,118 | 7,458 | $1.55M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.0% | 2,711 | 2,373 | $767K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.7% | 7,337 | 1,334 | $572K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.8% | 3,864 | 3,604 | $412K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 3.6% | 826 | 801 | $306K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.4% | 3,863 | 1,029 | $291K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.3% | 1,771 | 1,502 | $279K |
| 97139 | 2.1% | 3,426 | 593 | $178K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.7% | 2,238 | 1,868 | $147K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 1,358 | 1,110 | $140K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 738 | 514 | $137K |
83 more codes
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.4% | 502 | $121K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 1,407 | $102K |
| 80053 | Comprehensive metabolic panel | <1% | 7,753 | $82K |
| 97750 | <1% | 544 | $79K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 769 | $56K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,030 | $55K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,558 | $54K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,039 | $48K |
| 99070 | <1% | 4,846 | $46K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,332 | $45K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 871 | $44K |
| 80061 | Lipid panel | <1% | 2,410 | $33K |
| J3490 | Unclassified drugs | <1% | 2,771 | $27K |
| 87486 | <1% | 826 | $24K | |
| 87581 | <1% | 826 | $24K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 825 | $24K |
| 80306 | <1% | 1,235 | $22K | |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 141 | $22K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,504 | $22K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,131 | $22K |
| 99285 | Emergency room visit (most serious) | <1% | 37 | $20K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 689 | $19K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 62 | $18K |
| 71045 | Radiologic examination, chest; single view | <1% | 508 | $17K |
| 81001 | <1% | 3,075 | $15K | |
| 84439 | <1% | 1,179 | $11K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,839 | $11K |
| A0425 | Ground mileage, per statute mile | <1% | 251 | $11K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 207 | $9K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 163 | $8K |
| 84484 | <1% | 856 | $8K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 202 | $6K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 12 | $6K |
| 87088 | <1% | 887 | $6K | |
| 86140 | <1% | 1,299 | $6K | |
| 87507 | <1% | 14 | $5K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 67 | $4K |
| 83690 | <1% | 576 | $4K | |
| 81025 | <1% | 1,106 | $3K | |
| 80047 | <1% | 342 | $3K | |
| 93000 | <1% | 23 | $3K | |
| 83605 | <1% | 350 | $3K | |
| 83735 | <1% | 508 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 384 | $3K |
| 83874 | <1% | 217 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 843 | $3K |
| 82553 | <1% | 234 | $2K | |
| 82550 | <1% | 339 | $2K | |
| 84145 | <1% | 86 | $2K | |
| 85610 | <1% | 534 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 155 | $2K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 72 | $2K |
| 83880 | <1% | 56 | $2K | |
| 87077 | <1% | 177 | $1K | |
| 87040 | <1% | 156 | $1K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 37 | $1K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 168 | $1K |
| 87186 | <1% | 134 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 102 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 158 | $959.05 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 135 | $896.61 |
| 82077 | <1% | 63 | $867.21 | |
| 81003 | <1% | 349 | $682.37 | |
| 99000 | <1% | 93 | $676.66 | |
| 82803 | <1% | 43 | $535.62 | |
| 86803 | <1% | 42 | $527.94 | |
| 85027 | <1% | 93 | $489.99 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 56 | $381.29 |
| 82043 | <1% | 73 | $365.76 | |
| 83550 | <1% | 53 | $365.17 | |
| 83540 | <1% | 52 | $297.44 | |
| 87807 | <1% | 14 | $243.36 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 32 | $230.65 |
| 85651 | <1% | 77 | $182.96 | |
| 85730 | <1% | 31 | $165.54 | |
| 87070 | <1% | 15 | $112.65 | |
| 85007 | <1% | 25 | $67.75 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 12 | $49.44 |
| J2704 | Injection, propofol, 10 mg | <1% | 12 | $40.17 |
| 81015 | <1% | 14 | $35.00 | |
| 85652 | <1% | 13 | $31.20 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 15 | $2.25 |
| A6250 | Skin sealants, protectants, moisturizers, ointments, any type, any size | <1% | 19 | $0.57 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKRAMER, KEVIN (CEO)
| Provider | Location | Paid |
|---|---|---|
| Last Frontier Healthcare District | Alturas, CA | $3.64M |
| Last Frontier Healthcare District | Canby, CA | $2.54M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.